AI Skills Become ‘Non-Negotiable’ for Pharma’s Medical Science Liaisons

By Stephanie Lewis

As artificial intelligence reshapes industries, the pharmaceutical sector is no exception. Medical affairs teams, particularly Medical Science Liaisons (MSLs), are facing a new imperative: mastering AI to remain competitive and deliver impactful insights. This shift is driving demand for specialized training programs, with industry leaders warning that a lack of AI fluency could hinder career advancement and leave teams ill-equipped to navigate the evolving landscape.

The Rise of AI in Medical Affairs

The integration of AI into medical affairs isn't merely a futuristic concept; it's a present-day reality. According to recent industry reports, over 45% of medical affairs professionals are already exploring or implementing AI capabilities within their organizations. The benefits are multifaceted, ranging from streamlined literature reviews and accelerated data analysis to personalized engagement with Key Opinion Leaders (KOLs).

“AI is becoming essential for MSLs to efficiently process the overwhelming amount of scientific data, identify emerging trends, and deliver relevant insights to stakeholders,” explained a source within a leading pharmaceutical company. “It’s about augmenting their expertise, not replacing it.”

The BCMAS® Program Responds to the Demand

The Accreditation Council for Medical Affairs (ACMA) is at the forefront of this transformation, having recently integrated AI training into its flagship Board Certified Medical Affairs Specialist (BCMAS®) program. This move reflects a growing recognition within the industry that specialized training is no longer optional but a critical necessity.

“In the rapidly evolving life sciences landscape, AI literacy is not just an advantage, it’s a necessity,” stated William Soliman, Founder & CEO of ACMA. “The BCMAS® program is designed to equip MSLs with the skills and knowledge they need to thrive in this new era.”

The program focuses on practical applications of AI, including data analysis, content creation, and strategic decision-making. It aims to empower MSLs to leverage AI tools effectively and deliver impactful insights that drive brand strategy and R&D.

Competition Heats Up in AI Training

While ACMA is a prominent player, it's not alone in offering AI training for medical affairs professionals. Several other organizations, including CELforPharma, MSL Mastery, and LS Academy, are also offering specialized courses and programs. This increased competition reflects the growing demand for AI skills within the industry.

Each program emphasizes different aspects of AI, from foundational concepts to advanced applications. MSL Mastery, for instance, offers a program specifically focused on preparing MSLs for AI-related interview questions. LS Academy focuses on the use of tools like ChatGPT for processing scientific data.

Concerns over Skills Gaps and Career Prospects

Despite the growing availability of training programs, concerns remain about the potential for skills gaps within the medical affairs workforce. Experts warn that a lack of AI fluency could hinder career prospects and leave teams ill-equipped to compete in the evolving landscape.

“We’re already seeing a widening gap between those who embrace AI and those who resist it,” said an industry consultant specializing in medical affairs talent development. “MSLs who don’t invest in their AI skills risk becoming obsolete.”

Recent surveys support this assertion. One study revealed that nearly 70% of respondents found it more difficult to secure new roles, with a significant portion attributing this to a lack of AI skills. Furthermore, the study suggested that roles requiring complex interpersonal engagement and strategic thinking were less susceptible to automation, while those focused on data processing and routine tasks were at higher risk.

ROI and the Business Case for AI Training

Investing in AI training for MSLs isn’t just about avoiding obsolescence; it’s also about maximizing ROI and driving business value. Companies that prioritize AI training can expect to see improvements in efficiency, productivity, and strategic impact.

“AI can help MSLs automate labor-intensive tasks, accelerate decision-making, and deliver more personalized interactions with KOLs,” explained a pharmaceutical executive responsible for medical affairs training. “This translates into significant cost savings and improved brand performance.”

Furthermore, standardized AI competencies can enhance compliance and reduce risk, ensuring that MSLs are equipped to navigate the complex regulatory landscape.

The Future of MSLs in an AI-Driven World

The integration of AI into medical affairs is poised to reshape the role of MSLs in profound ways. While some tasks may be automated, the core competencies of MSLs – scientific expertise, interpersonal skills, and strategic thinking – will remain essential.

“AI will augment the capabilities of MSLs, not replace them,” asserted a source within ACMA. “The future of MSLs lies in their ability to leverage AI tools to deliver more impactful insights and build stronger relationships with stakeholders.”

Ultimately, the successful integration of AI into medical affairs will require a proactive approach to training, a commitment to continuous learning, and a willingness to embrace new technologies. Those who prioritize these elements will be well-positioned to thrive in the evolving landscape and unlock the full potential of AI-driven innovation.